Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 7 recruiting now early-phase tilt small index

Long COVID-19: early-phase trial registry

7 of 15 indexed Long COVID-19 trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,140 of 28,707 conditions by registered trial count.

15 US clinical trials · 7 currently recruiting · #1,140 of 28,707 conditions by registered trial count

Long COVID-19: 15 US clinical trials tracked, 7 recruiting.

Long COVID-19 is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Duke University, running 5 of these trials.

Enrollment posture brief

Registry condition long-covid-19

OPEN 7 | RECR 47% | LATE 1 | EARLY 8 | RANK #1140 | SPON 5

Nearest open-share peer: Autism (47% recruiting · 105 trials)

Advanced Lung Non-Small Cell53.3%Long COVID-19 (this)47%AIDS26.7%Adult Acute Myeloid Leukemia0%Adult Glioblastoma0%
Open-enrollment share among volume-matched conditions near Long COVID-19

Long COVID-19 lists 7 open slots (47% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Long COVID-19 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Long COVID-19 recruits in line with its size-band peers.

    7 of 15 indexed trials (46.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Long COVID-19 research.

    Duke University accounts for 5 of 15 trials (33.3%). 11 distinct sponsors appear on at least one study for this condition label.

  3. Typical Long COVID-19 enrolment sits around 300 participants.

    Median target enrolment is 300 among the 15 trials that report a genuine target (sentinel values excluded). 5 of those (33.3%) plan for fewer than 100 participants.

  4. Long COVID-19 research is mostly interventional.

    14 interventional and 1 observational studies make up this index (93.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 27Phase 31

Open and recent trials

15 total, page 1 of 1

RECRUITING NA 100,500 participants

The Long COVID-19 Wearable Device Study

Scripps Translational Science Institute

NCT05741112

RECRUITING NA 400 participants

Long-Covid-19 Alleviation Through Learning Mindfulness Study

Columbia University

NCT07140094

RECRUITING Phase 2 150 participants

AT1001 for the Treatment of Long COVID

Massachusetts General Hospital

NCT05747534

RECRUITING Phase 3 80 participants

Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19

Icahn School of Medicine at Mount Sinai

NCT06960928

RECRUITING Phase 2 50 participants

Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS

Vanderbilt University Medical Center

NCT07189936

RECRUITING Phase 2 40 participants

A Study to Examine Anktiva for the Treatment of COVID-19.

ImmunityBio

NCT07123727

RECRUITING Early Phase 1 30 participants

Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

University of Chicago

NCT06171152

ACTIVE NOT RECRUITING Phase 2 470 participants

RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD)

Duke University

NCT06404112

ACTIVE NOT RECRUITING Phase 2 361 participants

RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)

Duke University

NCT06404099

ACTIVE NOT RECRUITING NA 360 participants

RECOVER-ENERGIZE Platform Protocol_Appendix A (Exercise Intolerance)

Duke University

NCT06404060

ACTIVE NOT RECRUITING 300 participants

Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project

CND Life Sciences

NCT07005947

ACTIVE NOT RECRUITING Phase 2 200 participants

RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)

Kanecia Obie Zimmerman

NCT06305793

ACTIVE NOT RECRUITING NA 10 participants

A Pilot rTMS Trial for Neuropsychiatric Symptoms of Long-COVID

University of California, Los Angeles

NCT06586398

COMPLETED Phase 2 830 participants

RECOVER-SLEEP: Platform Protocol

Duke University

NCT06404086

COMPLETED NA 328 participants

RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms

Duke University

NCT05965739

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 7
Phase 3 1

Named interventions

Most-linked intervention names on Long COVID-19 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Solriamfetol Placebo Drug
2 trials
Modafinil Placebo Drug
2 trials
Solriamfetol Drug
2 trials
Modafinil Drug
2 trials
Melatonin Drug
2 trials
Placebo Drug
2 trials
tDCS-sham Device
1 trials
tDCS-active Device
1 trials

US sites by state

Facility locations filed on Long COVID-19 trials. A trial with sites in several states counts in each.

North Carolina 5 trials
California 4 trials
New York 2 trials
Illinois 2 trials
Arizona 2 trials
Tennessee 1 trials
Massachusetts 1 trials
Georgia 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Long COVID-19 page

15 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Long COVID-19 condition card totals 15 registered trials; most-linked intervention Solriamfetol Placebo; top US site state North Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.